Abstract: A method for determining the risk of acute kidney injury (AKI) in a mammal following cardiac surgery is provided. The method comprises determining the sample value of IL-6 or hFABP concentration, or the ratio of IL-6 to IL-10, in a biological sample from the mammal, either prior to cardiac surgery or within 6 hours following surgery; comparing the sample value to a corresponding reference value; and determining that the mammal is at risk of acute kidney injury following cardiac surgery if the sample value is greater than the corresponding reference value.

Abstract: Combination therapy with rivaroxaban and aspirin successfully reduces the risk of cardiovascular events in patients who have coronary artery disease and/or peripheral artery disease.

Abstract: A method for determining the risk of acute kidney injury (AKI) in a mammal following cardiac surgery is provided. The method comprises determining the sample value of IL-6 or hFABP concentration, or the ratio of IL-6 to IL-10, in a biological sample from the mammal, either prior to cardiac surgery or within 6 hours following surgery; comparing the sample value to a corresponding reference value; and determining that the mammal is at risk of acute kidney injury following cardiac surgery if the sample value is greater than the corresponding reference value.

Abstract: A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: A novel method for detecting the concentration of a metabolite in a fluid sample is provided. Devices for the detection of the analyte are also provided. In particular, a device for determining the concentration of 11-dehydro thromboxane in a urine sample and comparing it to a set of standardized quartile concentrations is provided. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: A method for assessing aspirin resistance and relative risk of a cardiovascular event in a patient taking aspirin is provided. The concentration of 11-dehydro-thromboxane B2 in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro-thromboxane B2 that falls within the second, third, or fourth quartile is indicative of aspirin resistance and an elevated risk of a recurrent cardiovascular event.

Abstract: A novel method for detecting the concentration of a metabolite in a fluid sample is provided. Devices for the detection of the analyte are also provided. In particular, a device for determining the concentration of 11-dehydro thromboxane in a urine sample and comparing it to a set of standardized quartile concentrations is provided. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.

Abstract: A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.